This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus pemetrexed or docetaxel in patients with advanced non-small lung cancer with specific gene profile involving the ALK gene after failure of one previous chemotherapy regimen that included one platinum drug.
Eligibility Criteria
Inclusion Criteria:
histologically or cytologically proven diagnosis of non-small cell lung cancer
positive for the ALK fusion gene (test provided by a central laboratory)
must have had disease progression after only one prior chemotherapy and that regimen but must have included one platinum drug
tumors must be measurable
Exclusion Criteria:
prior treatment with PF-02341066
current treatment in another clinical trial
Trial Contact Information
Trial Lead Organizations/Sponsors
Pfizer Incorporated Pfizer CT.gov Call Center Study Director
Pfizer CT.gov Call Center Ph: 1-800-718-1021
Pfizer Oncology Clinical Trial Information Service Ph: 1-877-369-9753 Email: [email protected]
Trial Sites
U.S.A. Washington Seattle
Pfizer Investigational Site Australia New South Wales Camperdown Pfizer Investigational Site South Australia Adelaide Pfizer Investigational Site Victoria Bentleigh Pfizer Investigational Site East Melbourne Pfizer Investigational Site Fitzroy Pfizer Investigational Site Footscray Pfizer Investigational Site Frankston Pfizer Investigational Site Parkville Pfizer Investigational Site Brazil Sao Paulo Barretos Pfizer Investigational Site Jau Pfizer Investigational Site Sao Paulo Pfizer Investigational Site Canada Quebec Montreal Pfizer Investigational Site China Beijing Pfizer Investigational Site Shanghai Pfizer Investigational Site France Villejuif Pfizer Investigational Site Germany Dresden Pfizer Investigational Site Essen Pfizer Investigational Site Grosshansdorf Pfizer Investigational Site Hamburg Pfizer Investigational Site Heidelberg Pfizer Investigational Site Koeln Pfizer Investigational Site Muenchen Pfizer Investigational Site Oldenburg Pfizer Investigational Site Wiesbaden Pfizer Investigational Site Hong Kong Hong Kong Pfizer Investigational Site Shatin, New Territories Pfizer Investigational Site Tuen Mun, New Territories Pfizer Investigational Site Hungary Budapest Pfizer Investigational Site Szekesfehervar Pfizer Investigational Site Italy Avellino Pfizer Investigational Site Lido di Camaiore (LU) Pfizer Investigational Site Lucca Pfizer Investigational Site Milano Pfizer Investigational Site Monza Pfizer Investigational Site Torino Pfizer Investigational Site Japan Tokyo Pfizer Investigational Site Netherlands Groningen Pfizer Investigational Site Republic of Korea Seoul Pfizer Investigational Site Russia Saint-Peterburg Pfizer Investigational Site Saint-Petersburg Pfizer Investigational Site St. Petersburg Pfizer Investigational Site Spain Barcelona Pfizer Investigational Site L'hospitalet de Llobregat Pfizer Investigational Site Sabadell Pfizer Investigational Site Sevilla Pfizer Investigational Site United Kingdom London Pfizer Investigational Site Manchester Pfizer Investigational Site Sutton Pfizer Investigational Site
Link to the current ClinicalTrials.gov record. NLM Identifer NCT00932893 Information obtained from ClinicalTrials.gov on April 17, 2012
Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.
